These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 9972142)
41. Up-regulation and coexpression of MIF and matrix metalloproteinases in human abdominal aortic aneurysms. Verschuren L; Lindeman JH; van Bockel JH; Abdul-Hussien H; Kooistra T; Kleemann R Antioxid Redox Signal; 2005; 7(9-10):1195-202. PubMed ID: 16115023 [TBL] [Abstract][Full Text] [Related]
42. Abdominal aortic aneurysm and cerebral aneurysm present different pathological evolutions and responses to pharmacological therapy. Zhou X; Ji WJ; Tu Y; Yao M; Li YM Med Hypotheses; 2007; 68(3):601-6. PubMed ID: 17030100 [TBL] [Abstract][Full Text] [Related]
43. Pharmacological targets in the treatment of abdominal aortic aneurysms. Bergoeing MP; Thompson RW; Curci JA Expert Opin Ther Targets; 2006 Aug; 10(4):547-59. PubMed ID: 16848691 [TBL] [Abstract][Full Text] [Related]
44. Matrix metalloproteinase-specific inhibition of Ca2+ entry mechanisms of vascular contraction. Chew DK; Conte MS; Khalil RA J Vasc Surg; 2004 Nov; 40(5):1001-10. PubMed ID: 15557917 [TBL] [Abstract][Full Text] [Related]
45. Doxycycline Therapy for Abdominal Aortic Aneurysm: Inhibitory Effect on Matrix Metalloproteinases. Paghdar S; Khan TM; Patel NP; Chandrasekaran S; De Sousa JFM; Tsouklidis N Cureus; 2021 May; 13(5):e14966. PubMed ID: 34123662 [TBL] [Abstract][Full Text] [Related]
46. Osteoclastogenesis in Abdominal Aortic Aneurysms: A New Therapeutic Target. Leung AD; Yamanouchi D Curr Drug Targets; 2018; 19(11):1233-1240. PubMed ID: 28950811 [TBL] [Abstract][Full Text] [Related]
47. Activation of transglutaminase type 2 for aortic wall protection in a rat abdominal aortic aneurysm formation. Munezane T; Hasegawa T; Suritala ; Tanaka A; Okada K; Okita Y J Vasc Surg; 2010 Oct; 52(4):967-74. PubMed ID: 20615646 [TBL] [Abstract][Full Text] [Related]
48. Regression of abdominal aortic aneurysms by simultaneous inhibition of nuclear factor kappaB and ets in a rabbit model. Miyake T; Aoki M; Masaki H; Kawasaki T; Oishi M; Kataoka K; Ogihara T; Kaneda Y; Morishita R Circ Res; 2007 Nov; 101(11):1175-84. PubMed ID: 17885220 [TBL] [Abstract][Full Text] [Related]
49. High-mobility group box 1 protein blockade suppresses development of abdominal aortic aneurysm. Kohno T; Anzai T; Kaneko H; Sugano Y; Shimizu H; Shimoda M; Miyasho T; Okamoto M; Yokota H; Yamada S; Yoshikawa T; Okada Y; Yozu R; Ogawa S; Fukuda K J Cardiol; 2012 May; 59(3):299-306. PubMed ID: 22365948 [TBL] [Abstract][Full Text] [Related]
50. Cigarette smoking increases aortic dilatation without affecting matrix metalloproteinase-9 and -12 expression in a modified mouse model of aneurysm formation. Bergoeing MP; Arif B; Hackmann AE; Ennis TL; Thompson RW; Curci JA J Vasc Surg; 2007 Jun; 45(6):1217-1227. PubMed ID: 17398058 [TBL] [Abstract][Full Text] [Related]
54. The influence of statins on the expansion rate and rupture risk of abdominal aortic aneurysms. VAN KUIJK JP; FLU WJ; WITTEVEEN OP; VOUTE M; BAX JJ; POLDERMANS D J Cardiovasc Surg (Torino); 2009 Oct; 50(5):599-609. PubMed ID: 19741575 [TBL] [Abstract][Full Text] [Related]
55. Uptake of tetracycline by aortic aneurysm wall and its effect on inflammation and proteolysis. Franklin IJ; Harley SL; Greenhalgh RM; Powell JT Br J Surg; 1999 Jun; 86(6):771-5. PubMed ID: 10383577 [TBL] [Abstract][Full Text] [Related]
57. Relationships between matrix metalloproteinases and tissue inhibitor of metalloproteinases in the wall of abdominal aortic aneurysms. Nishimura K; Ikebuchi M; Kanaoka Y; Ohgi S; Ueta E; Nanba E; Ito H Int Angiol; 2003 Sep; 22(3):229-38. PubMed ID: 14612849 [TBL] [Abstract][Full Text] [Related]
58. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. Pyo R; Lee JK; Shipley JM; Curci JA; Mao D; Ziporin SJ; Ennis TL; Shapiro SD; Senior RM; Thompson RW J Clin Invest; 2000 Jun; 105(11):1641-9. PubMed ID: 10841523 [TBL] [Abstract][Full Text] [Related]
59. Current Status and Perspectives on Pharmacologic Therapy for Abdominal Aortic Aneurysm. Yoshimura K; Morikage N; Nishino-Fujimoto S; Furutani A; Shirasawa B; Hamano K Curr Drug Targets; 2018; 19(11):1265-1275. PubMed ID: 29284386 [TBL] [Abstract][Full Text] [Related]
60. Influence of cardiovascular risk factors on levels of matrix metalloproteinases 2 and 9 in human abdominal aortic aneurysms. Dilmé JF; Bellmunt S; Camacho M; Solà-Villà D; Romero JM; Escudero JR; Vila L Eur J Vasc Endovasc Surg; 2014 Oct; 48(4):374-81. PubMed ID: 24980077 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]